In a landmark legal development that threatens to recalibrate the financial landscape of American healthcare, the U.S. Court of Appeals for the 5th Circuit has delivered a stinging rebuke to federal regulators regarding the implementation of the No Surprises Act (NSA). The ruling, handed down by a majority of the court’s 17 active judges, effectively invalidates key portions of the government’s methodology for calculating the Qualifying Payment Amount (QPA)—the critical benchmark used in the arbitration process to resolve payment disputes between healthcare providers and insurers.
This decision marks a significant shift in the ongoing tug-of-war between the insurance industry and medical provider groups, potentially cementing a "cottage industry" of dispute resolution that critics argue is driving up national healthcare spending.
Chronology: The Evolution of the No Surprises Act Conflict
The No Surprises Act, enacted in 2020, was designed as a watershed consumer protection measure, intended to shield patients from the financial shock of unexpected out-of-network medical bills. By and large, the law has succeeded in its primary mission, preventing millions of Americans from receiving catastrophic balance bills. However, the mechanism established to settle the resulting payment disputes—the Independent Dispute Resolution (IDR) process—has become a flashpoint for litigation.
The Regulatory Struggle
- 2021: The Department of Health and Human Services (HHS), along with the Departments of Labor and Treasury, promulgated rules establishing the QPA as the central benchmark for arbiters.
- 2023: In a major victory for medical associations, a Texas federal judge ruled that the government’s inclusion of "ghost rates"—contracted rates for services a provider does not actually perform—in the QPA calculation was illegal.
- 2024: The 5th Circuit initially overturned that lower court decision, handing a rare victory to the government and allowing insurers to continue including these low-value rates in their calculations.
- Late 2024 – Early 2025: Following intense pushback from provider groups, the 5th Circuit agreed to a rare en banc re-adjudication of the case.
- Present Day: The court has now reversed its earlier stance, siding with the Texas Medical Association (TMA) and other provider plaintiffs, declaring that the inclusion of ghost rates and specific incentive-based compensation in the QPA formula violates the intent of the NSA.
Supporting Data: Why the QPA Calculation Matters
At the heart of the dispute is the QPA, a metric intended to represent the median in-network rate for a given service in a specific geographic area. Insurers have long used this figure to anchor their offers in arbitration. However, providers contend that insurers have "gamed" the system by including artificially low rates—often as low as $0—to drag down the average.
The data suggests that the arbitration process is currently heavily skewed. According to industry statistics:
- Provider Success Rate: Medical providers are prevailing in approximately 85% of surprise billing cases that reach arbitration.
- Payment Disparity: In 87% of these cases, the final arbitrated award is significantly higher than the QPA offered by the insurer.
- The "Ghost" Effect: By including "ghost rates" (contracted rates for services a provider never actually performs), insurers have effectively deflated the QPA. Because providers have no incentive to negotiate these specific, non-performed services, these rates often hover near zero, skewing the mathematical median downward.
The 5th Circuit’s recent ruling explicitly addresses this, with the majority opinion stating that the QPA should strictly reflect rates for services actually furnished by a provider. The court further ruled that the government’s attempt to exclude risk-sharing, bonuses, and penalty-based compensation from the QPA was a misinterpretation of the law, which requires the benchmark to reflect the "highest possible amount" in a provider-insurer contract.
Official Responses and Perspectives
The ruling has sparked immediate and sharply divided reactions from stakeholders across the healthcare ecosystem.
The Provider Perspective
Dr. Bradford Holland, president of the Texas Medical Association (TMA), lauded the decision as a necessary correction. "This ruling is another step in the right direction for both patients and the physicians who care for them," Holland stated. Providers argue that the artificially low QPAs set by insurers have forced doctors to rely on the arbitration process just to receive fair market compensation for their expertise. They contend that the high win rate in arbitration is not evidence of a broken system, but rather evidence that the "benchmark" created by insurers was never representative of reality.
The Government’s Dilemma
Federal regulators at HHS, the Department of Labor, and the Department of Treasury now face a difficult path forward. They could choose to appeal the decision, though the political climate in Washington suggests a pivot may be imminent. Sources within the incoming administration have signaled a desire to "clean up" the process. During the summer of 2026, regulators indicated to the New York Times that they are actively working to reform the arbitration mechanisms, though the scope of those reforms remains a matter of intense speculation.
The Insurer Stance
Insurers view the ruling as a potential catalyst for a new era of medical inflation. With the 5th Circuit effectively removing the "artificially low" anchors from the arbitration process, insurance companies fear that the IDR process will become a pipeline for massive, uncontrolled payouts.
Broader Implications: The Cost of Care
The most significant consequence of the 5th Circuit’s decision may be its long-term impact on U.S. healthcare spending. Arbitration is already producing results that diverge wildly from historical norms. In one widely cited case, a plastic surgeon was awarded $440,000 for a breast reduction procedure—a surgery that typically commands a market rate between $15,000 and $25,000.
Such outliers are becoming increasingly common, according to research by the Brookings Institution and other policy analysts. When these costs are aggregated, the impact on the commercial insurance market is profound:
- Margin Compression: Health insurers are seeing their commercial business margins threatened by the sheer volume and scale of high-value arbitration awards.
- Premium Hikes: To compensate for these increased costs, insurers are expected to pass the financial burden onto employers and individual policyholders through rising premiums.
- Market Distortions: The "cottage industry" of dispute resolution, which has grown into a multibillion-dollar ecosystem of law firms and arbitration consultants, may see further expansion as the barrier to obtaining higher payouts is lowered.
The Road Ahead: Can the System Be Stabilized?
While the 5th Circuit did offer one concession to the government—agreeing that "single-case agreements" (common in the air ambulance industry) should be excluded from QPA calculations—the overall ruling serves as a massive win for providers.
The Centers for Medicare & Medicaid Services (CMS) did attempt to mitigate some of these issues earlier this spring by finalizing a rule aimed at reducing the backlog of ineligible disputes. However, the rule has faced criticism from all sides. Insurers argue the rule didn’t go far enough to stop the "gaming" of the system, while providers worry that new filing requirements might create unnecessary administrative hurdles.
As the legal battle shifts, the fundamental question remains: Can a federal arbitration system successfully balance the need to protect consumers from surprise bills with the necessity of maintaining a sustainable cost structure for the entire U.S. healthcare system? With the 5th Circuit’s latest ruling, the pendulum has swung decisively toward the providers, leaving regulators, insurers, and employers to grapple with the reality of an increasingly expensive, and litigious, medical billing landscape.
For the American patient, the immediate protection from surprise bills remains intact, but the secondary costs—manifested in premiums and broader economic inflation—may only just be beginning to manifest. As we look toward the remainder of the year, the legislative and regulatory focus will undoubtedly turn to whether Congress needs to intervene to rewrite the No Surprises Act to provide more concrete, inflation-resistant guidance for the IDR process.
